Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Newer birth control pill raises risk of blood clots

Two human trials in the US and the UK including women from both populations showed that women taking newer forms of oral contraceptives, which include drosperinone, a synthetic version of the hormone progesterone, increased their risk of developing a blood clots by two or three times over those taking older birth control pills that rely on a different form of the hormone known as levonorgestrel.

26 Apr 2011

Teva acknowledges promising results of DEFINE study in MS

We acknowledge the results of the DEFINE study seem promising for patients. It is important to note that as a general rule, results obtained in clinical trials in multiple sclerosis (MS) cannot be compared, unless agents are tested in a head-to-head manner in the same trial.

22 Apr 2011

Pharma Tech expands agreement for Shasta Genstrip

InstaCare Corp. a leading provider of prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that its operating subsidiary, Pharma Tech Solutions, Inc., has significantly expanded its agreement to control, manage and distribute the novel at-home diagnostic product, the Shasta Genstrip.

18 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that new preclinical data of their investigational compound custirsen in castrate resistant prostate cancer were presented this week at the 102nd Annual Meeting of the AACR.

7 Apr 2011

Scripted engages CW Rainmakers for Genmed awareness campaign

Genmed Holding Corp. is pleased to announce Scripted Consulting has engaged the services of CW Rainmakers (CW) as an integral part of Scripted's company awareness campaign presently underway for Genmed. Scripted and CW are taking the lead in spreading the word about GENM and its unique, competitive advantages in the generic drug industry.

5 Apr 2011

P&G, Teva sign partnership agreement for consumer health care

The Procter & Gamble Company and Teva Pharmaceutical Industries Ltd. today announced the signing of a master agreement to create a partnership in consumer health care by bringing together both companies' existing over-the-counter medicines and complementary capabilities to accelerate growth.

25 Mar 2011

Survey: AR symptoms continue to impact patients' daily activities

Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.

22 Mar 2011

Investissement Québec provides financial support to Algorithme Pharma

Algorithme Pharma Inc., a Canadian clinical contract research organization, with facilities in Laval Québec, Montréal Québec, and through its sister company Simbec Research Limited in Merthyr Tydfil UK, today announced having secured the support of Investissement Québec in the form of a loan.

21 Mar 2011

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

Teva Pharmaceutical Industries Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NOMAC-E2, an investigational contraceptive pill combining 1.5 mg of 17-beta-estradiol with 2.5 mg of nomegestrol acetate in a 24/4 monophasic regimen.

18 Mar 2011

Study evaluates potential national savings from discount generic medication programs

If all eligible patients filled their prescriptions through a $4 generic drug program, the societal savings could amount to nearly $6 billion, according to a University of Pittsburgh Graduate School of Public Health study.

15 Mar 2011

Indium oxine in development at Positron's Crown Point facility

Positron Corporation a molecular imaging company announced today that it is developing indium oxine, a radiopharmaceutical widely used for the radiolabeling of blood elements. This project signifies Positron's entrance into direct radiopharmaceutical manufacturing and sales; indium oxine is the first new product in development at Positron's research, development and manufacturing facility in Crown Point, Indiana.

14 Mar 2011

Walgreens sells Pharmacy Benefits Manager to Catalyst Health Solutions

Catalyst Health Solutions Inc said it will buy Walgreen Co's pharmacy benefits management unit for about $525 million in cash, a deal that might spur more consolidation before big generic drug launches that could boost the business.

11 Mar 2011

Canadian House of Commons passes bill that could ease access to generic drugs in developing countries

Canadian lawmakers in the country's House of Commons on Wednesday "approved a bill aiming to ease the process that lets generic drug manufacturers produce patented medicines for export to poor nations at cheaper prices in a move the pharmaceutical industry says could undermine intellectual property rights," Bloomberg reports.

11 Mar 2011

Trial date set for Teva's generic COPAXONE patent infringement litigation against Momenta

Teva Pharmaceutical Industries Ltd. today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).

2 Mar 2011

Star-Ledger examines Tibotec's agreement with generic drug makers on experimental HIV/AIDS treatment

In a piece on the move by drug manufacturer Tibotec Pharmaceuticals to grant licenses to generic manufacturers in India and South Africa to create copies of its experimental HIV/AIDS drug, the New Jersey Star-Ledger examines why drug companies are particularly focused on expanding their reach in sub-Saharan Africa.

1 Mar 2011

UBC study shows Canadians and Americans receive different drug information online

Americans and Canadians are getting vastly different search results when they look up prescription drug information online, says a study by researchers at the University of British Columbia.

24 Feb 2011

NCPA, NACDS explain importance of pharmacies in Medicaid program

The National Association of Chain Drug Stores and the National Community Pharmacists Association have sent a joint letter to every Governor and State Medicaid Director, explaining the importance of pharmacies in Medicaid, offering recommendations, and expressing a desire to work together to cut costs without endangering Medicaid beneficiaries' access to pharmacy prescription drug services.

21 Feb 2011

Medicare pay cut for docs already drawing fire

Critics said the method used in the budget blueprint would cause serious problems. But some news reports indicate the inclusion of this Medicare "doc fix" would help build support within the physician community for the president's health care agenda.

16 Feb 2011